Alzheimer's biomarkers may forecast dementia progression in people 80 and older
Cognitive decline in very old adults has been considered for decades to be an almost inevitable consequence of aging. In clinical practice, this has contributed to many memory problems in patients over age 80 being interpreted as a natural part of aging, without further investigation into their cause. However, this view is increasingly being challenged as knowledge of neurodegenerative diseases advances and more accurate tools for their detection become available.
edited by Sadie Harley , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
A study led by researchers at the Sant Pau Research Institute (IR Sant Pau) and published in Neurology provides new evidence on the value of Alzheimer's disease biomarkers in this age group.
The study, which focused on people aged 80 and older with mild cognitive impairment, shows that the presence of Alzheimer's disease biology—determined using biomarkers in cerebrospinal fluid and blood—is not only common but also consistently associated with a greater risk of more rapid cognitive decline and progression to dementia.
These findings challenge the still widespread belief that biomarkers have limited value at very advanced ages because of the coexistence of multiple conditions. On the contrary, the study shows that, even within this more clinically complex context, identifying the underlying pathology continues to provide relevant information about patients' progression.